EBMT 2023 | Novel dual-targeting CD19/22 CAR-T therapy in relapsed ALL
Antonio Pérez-Martínez, MD, PhD, La Paz University Hospital, Madrid, Spain, shares insight into a novel dual-targeting CD19/22 CAR-T therapy for patients with acute lymphoblastic leukemia (ALL). Whilst CD19 CAR-T therapy has been revolutionary for the treatment of ALL, relapse can occur in up to 50% of patients. Dr Pérez-Martínez goes on to discuss the preliminary results from a small cohort of patients that underwent CD19/22 CAR-T infusion following relapse on CD19 CAR-T therapy. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
